Cantel Medical Financial Statements (CMD)
|
|
|
|
Report date
|
|
|
29.09.2016 |
28.09.2017 |
27.09.2018 |
25.09.2019 |
25.09.2020 |
|
28.05.2021 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
664.8 |
770.2 |
871.9 |
918.2 |
1 016 |
|
1 216 |
|
Operating Income, bln rub |
|
|
97.3 |
110.5 |
122.8 |
84.8 |
48.3 |
|
154.3 |
|
EBITDA, bln rub |
? |
|
122.4 |
144.0 |
157.6 |
127.2 |
122.7 |
|
236.4 |
|
Net profit, bln rub |
? |
|
60.0 |
71.4 |
91.0 |
55.0 |
13.7 |
|
66.4 |
|
|
OCF, bln rub |
? |
|
80.3 |
108.2 |
125.9 |
66.9 |
136.9 |
|
166.1 |
|
CAPEX, bln rub |
? |
|
18.9 |
27.1 |
37.7 |
95.4 |
33.8 |
|
42.7 |
|
FCF, bln rub |
? |
|
61.4 |
81.1 |
88.2 |
-28.5 |
103.1 |
|
123.4 |
|
Dividend payout, bln rub
|
|
|
5.01 |
5.84 |
7.09 |
8.35 |
4.47 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
8.35% |
8.18% |
7.79% |
15.2% |
32.6% |
|
0 |
|
|
OPEX, bln rub |
|
|
211.9 |
256.8 |
292.3 |
343.9 |
387.7 |
|
435.3 |
|
Cost of production, bln rub |
|
|
355.6 |
403.0 |
458.0 |
490.7 |
580.1 |
|
626.4 |
|
R&D, bln rub |
|
|
15.4 |
18.4 |
24.6 |
31.3 |
32.4 |
|
31.0 |
|
Interest expenses, bln rub |
|
|
3.41 |
4.30 |
5.29 |
9.51 |
41.4 |
|
60.7 |
|
|
Assets, bln rub |
|
|
694.5 |
786.4 |
963.7 |
1 070 |
2 072 |
|
2 031 |
|
Net Assets, bln rub |
? |
|
454.4 |
523.9 |
608.9 |
661.5 |
729.6 |
|
817.2 |
|
Debt, bln rub |
|
|
116.0 |
126.0 |
197.3 |
230.9 |
1 059 |
|
891.6 |
|
Cash, bln rub |
|
|
28.4 |
36.6 |
94.1 |
44.5 |
277.9 |
|
218.5 |
|
Net debt, bln rub |
|
|
87.6 |
89.4 |
103.2 |
186.3 |
781.2 |
|
673.0 |
|
|
Ordinary share price, rub |
|
|
66.9 |
74.2 |
92.7 |
92.3 |
47.3 |
|
81.4 |
|
Number of ordinary shares, mln |
|
|
41.6 |
41.7 |
41.7 |
41.8 |
42.8 |
|
42.2 |
|
|
Market cap, bln rub |
|
|
2 787 |
3 096 |
3 867 |
3 855 |
2 024 |
|
3 437 |
|
EV, bln rub |
? |
|
2 875 |
3 186 |
3 970 |
4 041 |
2 805 |
|
4 110 |
|
Book value, bln rub |
|
|
62 |
88 |
103 |
142 |
-411 |
|
-304 |
|
|
EPS, rub |
? |
|
1.44 |
1.71 |
2.18 |
1.32 |
0.32 |
|
1.57 |
|
FCF/share, rub |
|
|
1.47 |
1.94 |
2.12 |
-0.68 |
2.41 |
|
2.92 |
|
BV/share, rub |
|
|
1.50 |
2.11 |
2.48 |
3.40 |
-9.59 |
|
-7.19 |
|
|
EBITDA margin, % |
? |
|
18.4% |
18.7% |
18.1% |
13.9% |
12.1% |
|
19.4% |
|
Net margin, % |
? |
|
9.02% |
9.27% |
10.4% |
5.99% |
1.35% |
|
5.46% |
|
FCF yield, % |
? |
|
2.20% |
2.62% |
2.28% |
-0.74% |
5.09% |
|
3.59% |
|
ROE, % |
? |
|
13.2% |
13.6% |
15.0% |
8.32% |
1.88% |
|
8.12% |
|
ROA, % |
? |
|
8.63% |
9.08% |
9.45% |
5.14% |
0.66% |
|
3.27% |
|
|
P/E |
? |
|
46.5 |
43.4 |
42.5 |
70.0 |
147.7 |
|
51.8 |
|
P/FCF |
|
|
45.4 |
38.2 |
43.8 |
-135.2 |
19.6 |
|
27.9 |
|
P/S |
? |
|
4.19 |
4.02 |
4.43 |
4.20 |
1.99 |
|
2.83 |
|
P/BV |
? |
|
44.7 |
35.2 |
37.4 |
27.2 |
-4.93 |
|
-11.3 |
|
EV/EBITDA |
? |
|
23.5 |
22.1 |
25.2 |
31.8 |
22.9 |
|
17.4 |
|
Debt/EBITDA |
|
|
0.72 |
0.62 |
0.65 |
1.46 |
6.37 |
|
2.85 |
|
|
R&D/CAPEX, % |
|
|
81.6% |
67.9% |
65.4% |
32.8% |
95.8% |
|
72.6% |
|
|
CAPEX/Revenue, % |
|
|
2.84% |
3.51% |
4.32% |
10.4% |
3.33% |
|
3.51% |
|
| Cantel Medical shareholders |
